CalAmp Corp. provides in telematics systems, and software and subscription services in the United States, Europe, the Middle East, Africa, South America, Asia and Pacific Rim, and internationally. The company offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things market, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. It also provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service applications. In addition, the company offers professional services, including project management, engineering services, and installation services. It sells its products and services to customers in the automotive, insurance, transportation and logistics, government, K12, industrial and construction equipment markets through direct sales organization, a channel partner program, and sales representatives, as well as its Websites and digital platform. The company was founded in 1981 and is headquartered in Irvine, California.
IPO Year: 2024
Exchange: NASDAQ
Website: calamp.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $8.00 | Outperform | Wedbush |
| 11/5/2024 | Outperform | William Blair | |
| 11/5/2024 | $18.00 | Overweight | Piper Sandler |
| 11/5/2024 | $23.00 | Overweight | JP Morgan |
| 8/16/2022 | $8.00 → $10.00 | Hold → Buy | Craig Hallum |
| 12/22/2021 | $15.00 → $14.00 | Buy | Canaccord Genuity |
| 12/22/2021 | $14.00 → $10.00 | Buy → Hold | Craig-Hallum |
| 9/24/2021 | $16.00 → $14.00 | Buy | Craig Hallum |
| 6/25/2021 | $19.00 → $18.50 | Buy | Roth Capital |
| 6/25/2021 | $15.00 → $16.00 | Buy | Craig Hallum |
Fastest customizable press release news feed in the world
Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell Therapy (ASGCT) Annual MeetingInitiating GLP toxicology studies evaluating CMP-SYNGAP-01 in Q3 2025Dosing completed in multiple ascending dose (MAD) cohort 3 of CMP-CPS-001 and data from single ascending dose (SAD) & MAD cohorts expected in Q4 2025 CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to u
Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs) Patient safety and pharmacokinetic data from single ascending dose (SAD) cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers highlighted CAMBRIDGE, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting th
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-0
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025 – Initiation of expansion into Phase 1b clinical trial in female OTC heterozygotes expected in Q2 2025 – Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025 CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics de
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William
IRVINE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a global technology leader in telematics and fleet intelligence, is excited to announce its participation in the STN East Conference on March 24, 2025. The CalAmp Synovia team will be stationed at Booth 108, where they will connect with student transportation professionals and share insights on the latest trends shaping the industry. With over 1,000 school districts in the US and Canada relying on CalAmp's cutting-edge solutions, the company continues to lead the way in GPS tracking, fleet optimization, and student safety. Attendees visiting Booth 108 will have the opportunity to engage with friendly and knowledgeabl
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences: Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate PresentationDate and Time: February 12, 2025, 10:00 a.m. ESTLocation: VirtualWebcast Link: Click Here Leerink Partners Global Healthcare ConferenceFormat: Fireside ChatDate and Time: March 1
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 15, 2025, at 3:45 p.m. PST. The event will be webcast live and can be accessed on the investor relations page of CAMP4's website at www.investors.camp4tx.com. A replay of the webcast will be archived on the C
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)
8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)
8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
DEFA14A - Camp4 Therapeutics Corp (0001736730) (Filer)
DEF 14A - Camp4 Therapeutics Corp (0001736730) (Filer)
S-8 - Camp4 Therapeutics Corp (0001736730) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wedbush initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $8.00
William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform
Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00
JP Morgan initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $23.00
Craig Hallum upgraded CalAmp from Hold to Buy and set a new price target of $10.00 from $8.00 previously
Canaccord Genuity reiterated coverage of CalAmp with a rating of Buy and set a new price target of $14.00 from $15.00 previously
Craig-Hallum downgraded CalAmp from Buy to Hold and set a new price target of $10.00 from $14.00 previously
Craig Hallum reiterated coverage of CalAmp with a rating of Buy and set a new price target of $14.00 from $16.00 previously
Roth Capital reiterated coverage of CalAmp with a rating of Buy and set a new price target of $18.50 from $19.00 previously
Craig Hallum reiterated coverage of CalAmp with a rating of Buy and set a new price target of $16.00 from $15.00 previously
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13G/A - CalAmp Corp. (0000730255) (Subject)
SC 13G/A - CalAmp Corp. (0000730255) (Subject)
SC 13G/A - CalAmp Corp. (0000730255) (Subject)
SC 13G/A - CalAmp Corp. (0000730255) (Subject)
SC 13G/A - CalAmp Corp. (0000730255) (Subject)
Live finance-specific insights
IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5
IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla
IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add
IRVINE, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its second quarter of fiscal year 2024 ended August 31, 2023. Second Quarter Fiscal Year 2024 Financial Overview Total revenue was $61.7 million in the quarter, representing a $9.2 million decline sequentially and an $11.1 million decline year over year. Gross margin in the quarter decreased 200 basis points sequentially and 370 basis points year over year to 36.2% as a result of lower volumes and shift in product mix driven by strong shipments to industrial customers.Softw
IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 second quarter financial results after market close on Thursday, October 5, 2023. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on October 5, 2023, to discuss its financial results. The conference call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at www.calamp.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software.
Gross Margin increases 280 basis points and Adjusted EBITDA remained strong in the quarter at $6.0 million The Company's Board of Directors has decided to explore strategic alternatives IRVINE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its first quarter of fiscal year 2024 ended May 31, 2023. First Quarter Fiscal Year 2024 Financial Overview Total revenue was $70.9 million in the quarter, a $7.6 million decline sequentially and $6.2 million increase year over year.Software and Subscription Services (
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 first quarter financial results after market close on Monday, July 10, 2023. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on July 10, 2023 to discuss its financial results. The conference call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at www.calamp.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A replay
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its fourth quarter and fiscal year 2023 ended February 28, 2023. "Fourth quarter results were highlighted by a significant increase in Adjusted EBITDA driven by a combination of gross margin increases and expense management," said Jeff Gardner, CalAmp's president and CEO. "The Company significantly reduced expenses through a restructuring late in Q4 to align the organization to a recurring revenue business model. As we enter this next fiscal year, our primary objective is to in
IRVINE, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps people and organizations improve operational performance, today announced that it will release its fiscal 2023 fourth quarter and full year financial results after market close on Thursday, April 27, 2023. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on April 27, 2023 to discuss its financial results. The conference call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at www.calamp.com. Please go to the website at least 15 minutes early to register, download and install any nec
Total consolidated revenue increases 8% sequentially to $78.9 million Software and Subscription Services revenue increases 11% sequentially to $49.3 million IRVINE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2023 ended November 30, 2022. "Revenue in the quarter exceeded the high-end of our expectations as increased supply allowed us to ship aged backlog to strategic customers," said Jeff Gardner, CalAmp's President and CEO. "This increased supply included devices incorporating components
Live Leadership Updates
Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th
IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv
IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, today announced that Jeff Gardner will be stepping down from his role as Chief Executive Officer, effective no later than October 30, 2023. The Company has commenced a search for its next CEO and will be retaining an executive search firm. In announcing his departure, Jeff Gardner shared, "It has been a privilege working with the amazing group of colleagues at CalAmp. I am proud of all that we have accomplished and the progress we have made in positioning the Company for growth and p
IRVINE, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps people and organizations improve operational performance, today announced that effective January 9, 2023, Jikun Kim, 58, will commence employment as Senior Vice President and Chief Financial Officer of CalAmp Corp. (the "Company"). Mr. Kim will serve as principal financial officer and principal accounting officer. Xiaolian (Cindy) Zhang will cease service as Interim Chief Financial Officer, and will continue to serve as Senior Vice President, Financial Planning and Analysis, and Erik Schulz will cease service as Interim Principal Accounting Officer, and will continue to serve
Mr. Cohenour brings 30+ years of executive leadership experience in IoT, mobile communications and semiconductors to Blackline Blackline Safety Corp. (TSX:BLN), a global leader in connected safety technology, today announced the appointment of Jason W. Cohenour, former President and CEO at Sierra Wireless, as a new member of its Board of Directors. Mr. Cohenour brings many years of executive leadership, sales, operations, and international M&A experience to the Blackline Safety Board. He previously served as President, CEO, and Director at Sierra Wireless, Inc. (TSX:SW, NASDAQ:SWIR) from 2005 to 2018. While CEO, Mr. Cohenour led a successful business turn-around, resulting in revenue gro
IRVINE, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, today announced the appointment of Wes Cummins, Founder and Chief Executive Officer of B. Riley Asset Management, LLC ("BRAM"), to its Board of Directors (the "Board"), effective immediately. In connection with today's announcement, CalAmp has entered into a cooperation agreement with BRAM and one of its managed funds. "We are pleased to welcome Wes to the CalAmp Board, and believe his background as a technology investor and unique insight into our industry will bring valuable persp
IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, today announced the appointment of Brennen Carson as its chief revenue officer (CRO). As CRO, Carson will help accelerate CalAmp's penetration into the transportation and logistics marketplace and drive sustainable revenue streams. Carson brings over 15 years of experience in enterprise software-as-a-service (SaaS) sales, directing cross-functional small-to-medium-sized business, mid-market and enterprise teams to drive top-line revenue. Most recently, Carson served as senior vice pr
IRVINE, Calif., Jan. 27, 2022 /PRNewswire/ -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping businesses and people track, monitor and recover vital assets with real-time visibility and insights, today announced the appointment of Mark Gaydos as its chief marketing officer (CMO). Gaydos will lead CalAmp's worldwide marketing strategy, go-to-market execution, branding and demand creation to help promote CalAmp's mission to automate and optimize transportation and logistics operations with its wide array of leading connected intelligence solutions. Gaydos brings more than 25 years of enterprise software marketing experience helping numerous technology companies build leadership